It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hyperpolarized 13C MRI visualizes real-time metabolic processes in vivo. In this study, we achieved high 13C polarization in situ in the bore of an MRI system for precursor molecules of most widely employed hyperpolarized agents: [1-13C]acetate and [1-13C]pyruvate ethyl esters in their perdeuterated forms, enhancing hyperpolarization lifetimes, hyperpolarized to P13C ≈ 28% at 80 mM concentration and P13C ≈ 19% at 10 mM concentration, respectively. Using vinyl esters as unsaturated Parahydrogen-Induced Polarization via Side-Arm Hydrogenation (PHIP-SAH) precursors and our novel polarization setup, we achieved these hyperpolarization levels by fast side-arm hydrogenation in acetone-d6 at elevated temperatures (up to 90°C) and hydrogenation pressures (up to 32 bar). We optimized the hyperpolarization process, reducing it to under 10 s, and employed advanced pulse sequences to enhance the polarization transfer efficiency. The hyperpolarization system has a small footprint, allowing it to be positioned in the same magnet, where 13C MRI is performed. We exemplified the utility of the design with sub-second in situ 13C MRI of ethyl [1-13C]pyruvate-d6. However, challenges remain in side-arm cleavage and purification in the MRI system to extract highly polarized aqueous agent solutions. Our results showcase efficient and rapid 13C hyperpolarization of these metabolite precursors in an MRI system with minimal additional hardware, promising to enhance future throughput and access to hyperpolarized 13C MRI.
Hyperpolarized 13C MRI visualizes real-time metabolic processes in vivo, however, external polarizers are commonly required to produce hyperpolarized metabolites. Here, using a parahydrogen-based approach, the authors achieved up to 30% 13C polarization in situ in an MRI system for precursor molecules [1-13C]acetate and [1-13C]pyruvate ethyl esters in their perdeuterated forms, potentially facilitating future metabolic imaging applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 University of Freiburg, Division of Medical Physics, Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9)
2 University of Freiburg, Division of Medical Physics, Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9); German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), partner site Freiburg, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
3 University Medical Center Schleswig-Holstein and Kiel University, Section Biomedical Imaging, Molecular Imaging North Competence Center (MOINCC), Department of Radiology and Neuroradiology, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)
4 Kiel University, Otto Diels Institute for Organic Chemistry, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)
5 German Cancer Research Center (DKFZ), Division of Translational Molecular Imaging, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
6 Wayne State University, Integrative Biosciences (Ibio), Department of Chemistry, Karmanos Cancer Institute (KCI), Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807)
7 University of Freiburg, Division of Medical Physics, Department of Diagnostic and Interventional Radiology, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany (GRID:grid.5963.9); German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), partner site Freiburg, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); Wayne State University, Integrative Biosciences (Ibio), Department of Chemistry, Karmanos Cancer Institute (KCI), Detroit, USA (GRID:grid.254444.7) (ISNI:0000 0001 1456 7807)